title: Decreased urokinase receptor expression by overexpression of the plasminogen activator in a colon cancer cell line.
abstract: There is now ample evidence that the proteolytic action of urokinase (UK) is potentiated by a specific cell surface receptor. The present study was undertaken to determine the role of UK as a modulator of its binding site. GEO colonic cells, which secrete low levels of UK (approximately 2.5 ng/ml per 72 h per 10(6) cells) and display approx. 10(4) receptors per cell, the majority of which are vacant, were transfected with an exogenous UK gene driven by the RSV long terminal repeat (LTR) promoter (pRSVUK). Several UK-overexpressing pRSVUK clones were identified by an e.l.i.s.a., Northern blotting and Southern blotting, and analysed for receptor numbers after an acid pretreatment which dissociates receptor-bound UK. pRSVUK GEO clones, expressing high levels of UK, consistently bound 50-75% less radioactive di-isopropylfluorophosphate (DFP)-UK than clones harbouring the selectable marker gene neo only or control GEO cells. Cross-linking experiments with a radioactive N-terminal fragment of UK which binds to the receptor showed a decreased amount of a binding protein of approx. 51 kDa in representative pRSVUK-transfected cells. Saturation and Scatchard analysis indicated that this reduction in radioligand binding reflected a 40-70% decrease in the number of UK receptors, rather than a change in the dissociation constant. The reduction in receptor display could be accounted for by a decrease in the amount of steady-state mRNA encoding the receptor. Radioactive DFP-UK binding to pRSVUK GEO clones, which display two-thirds less receptors than their neo counterparts, could be restored to control levels (untreated cells harbouring neo) by cultivating them in the presence of an antibody which inhibits the interaction of UK with its receptor. These data suggest that for one colonic cell line at least, UK reduces the expression of its own binding site via an autocrine stimulation of its cell surface receptor.
authors.affiliation: Institute of Microbiology, University of Copenhagen, Denmark.
authors.forename: W
authors.initials: W
authors.lastname: Hollas
authors.forename: E
authors.initials: E
authors.lastname: Soravia
authors.forename: A
authors.initials: A
authors.lastname: Mazar
authors.forename: J
authors.initials: J
authors.lastname: Henkin
authors.forename: F
authors.initials: F
authors.lastname: Blasi
authors.forename: D
authors.initials: D
authors.lastname: Boyd
mesh_terms: D015152:Blotting, Northern; D015139:Blotting, Southern; D003110:Colonic Neoplasms / Q000378:metabolism*; D003432:Cross-Linking Reagents; D004273:DNA, Neoplasm / Q000378:metabolism; D015870:Gene Expression; D006868:Hydrolysis; D010957:Plasmids; D010960:Plasminogen Activators / Q000235:genetics*; D012334:RNA, Neoplasm / Q000378:metabolism; D011956:Receptors, Cell Surface / Q000235:genetics*; D055293:Receptors, Urokinase Plasminogen Activator; D014162:Transfection; D014407:Tumor Cells, Cultured; D014568:Urokinase-Type Plasminogen Activator / Q000378:metabolism*
chemical_list: D003432:Cross-Linking Reagents; D004273:DNA, Neoplasm; D012334:RNA, Neoplasm; D011956:Receptors, Cell Surface; D055293:Receptors, Urokinase Plasminogen Activator; D010960:Plasminogen Activators; D014568:Urokinase-Type Plasminogen Activator